Becton Dickinson vs Boston Scientific
BDX and BSX side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BDX and BSX compare
Becton Dickinson and Boston Scientific are about the same size, with market caps of $54.0B and $60.8B.
On earnings, Boston Scientific is cheaper: it trades at 17.0× trailing earnings, against 59.9× for Becton Dickinson.
Becton Dickinson grew revenue faster over the last twelve months (17.4% versus 13.5% for Boston Scientific).
Becton Dickinson pays a dividend yielding 2.1%; Boston Scientific does not pay one.
Boston Scientific scores higher on the StockData Score (14 against 13 for Becton Dickinson), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BDX | BSX |
|---|---|---|
| Size and price | ||
| Market cap | $54.0B | $60.8B |
| Share price | $198.34 | $41.98 |
| Change, 1 year | 7.7% | −58.1% |
| Change, 5 years | −18.6% | −2.7% |
| Beta (5Y) | 0.51 | 0.77 |
| Employees | 72K | 59K |
| StockData Score | ||
| Total score | 13 | 14 (better) |
| Valuation score | 2 | 6 (better) |
| Growth score | 3 | 4 (better) |
| Performance score | 3 (better) | 1 |
| Health score | 2 | 3 (better) |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 59.9× | 17.0× (better) |
| P/S | 2.3× (better) | 2.9× |
| P/B | 2.2× (better) | 2.4× |
| EV/EBITDA | 14.1× | 13.1× (better) |
| P/FCF | 16.9× | 16.8× (better) |
| PEG | – | 0.27 |
| FCF yield | 5.9% | 6.0% (better) |
| Fair value | $183.90 | $93.08 |
| Margin of safety | −7.9% | 54.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 17.4% (better) | 13.5% |
| Revenue growth, 5Y average | 6.3% | 15.2% (better) |
| Net income growth (TTM) | −40.6% | – |
| EPS growth (TTM) | −39.6% | 47.0% (better) |
| EPS growth, 5Y average | 16.5% | – |
| Profitability | ||
| Gross margin | 46.9% | 69.9% (better) |
| Operating margin | 10.7% | 19.8% (better) |
| Net margin | 4.0% | – |
| FCF margin | 13.8% | 17.3% (better) |
| Return on equity | 3.8% | – |
| Return on invested capital | 5.1% | 11.2% (better) |
| Financial health | ||
| Debt / equity | 0.69 | 0.51 (better) |
| Net debt / EBITDA | 3.23 | 2.17 (better) |
| Interest coverage | 4.2× | 11.4× (better) |
| Current ratio | 0.87 | 1.24 (better) |
| Altman Z-score | 2.30 | 2.87 (better) |
| Piotroski F-score | 5 | – |
| Dividends and buybacks | ||
| Dividend yield | 2.1% | – |
| Payout ratio | 125% | – |
| Years of dividend growth | 12 | – |
| Dividend growth, 5Y average | 5.7% | – |
| Buyback yield | 4.6% | – |
| Shareholder yield | 6.7% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 102% | 92.1% |
| Held by insiders | 0.21% | 0.19% |
| Insider net buying, 12 months | −$2.8M (better) | −$13.0M |
| Superinvestors holding | 2 (better) | 1 |
| Short interest, % of float | 3.6% | 2.9% |
Go deeper
- BDX stock overview
- BDX income statement
- BDX valuation and score
- BSX stock overview
- BSX income statement
- BSX valuation and score
Other comparisons
- BAX vs BDX
- BAX vs BSX
- BDX vs GEHC
- BDX vs MDLN
- BDX vs MMM
- BDX vs SYK
- BSX vs GEHC
- BSX vs MDLN
- BSX vs MDT
- BSX vs MMM
- BSX vs SYK
For information only, not investment advice. Check the source filings before relying on any figure.